Analysts Set Galapagos NV (NASDAQ:GLPG) PT at $36.50

Galapagos NV (NASDAQ:GLPG) has been given an average rating of “Hold” by the seven brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $36.50.

A number of analysts have recently commented on the stock. Raymond James Financial reiterated a “market perform” rating on shares of Galapagos in a research note on Tuesday, February 24th. Royal Bank Of Canada increased their price objective on shares of Galapagos from $32.00 to $33.00 and gave the company a “sector perform” rating in a research report on Tuesday, February 24th. UBS Group restated a “market perform” rating on shares of Galapagos in a report on Tuesday, February 24th. Wall Street Zen raised shares of Galapagos from a “sell” rating to a “hold” rating in a research report on Tuesday, December 30th. Finally, Weiss Ratings raised Galapagos from a “sell (d)” rating to a “hold (c)” rating in a report on Thursday, February 26th.

Galapagos Trading Up 3.1%

NASDAQ GLPG opened at $32.70 on Friday. Galapagos has a one year low of $22.59 and a one year high of $37.78. The stock has a 50-day moving average of $33.63 and a 200 day moving average of $32.84.

Institutional Trading of Galapagos

A number of hedge funds have recently bought and sold shares of GLPG. XTX Topco Ltd boosted its position in Galapagos by 92.6% in the fourth quarter. XTX Topco Ltd now owns 23,219 shares of the biotechnology company’s stock worth $759,000 after purchasing an additional 11,162 shares during the last quarter. Millennium Management LLC grew its stake in shares of Galapagos by 121.9% during the 4th quarter. Millennium Management LLC now owns 339,354 shares of the biotechnology company’s stock valued at $11,097,000 after purchasing an additional 186,452 shares during the period. Madison Avenue Partners LP increased its position in shares of Galapagos by 0.8% during the 4th quarter. Madison Avenue Partners LP now owns 2,213,169 shares of the biotechnology company’s stock valued at $72,371,000 after purchasing an additional 17,394 shares during the last quarter. Man Group plc increased its position in shares of Galapagos by 31.5% during the 4th quarter. Man Group plc now owns 47,581 shares of the biotechnology company’s stock valued at $1,556,000 after purchasing an additional 11,384 shares during the last quarter. Finally, Kotler Kevin bought a new position in shares of Galapagos in the 4th quarter worth approximately $2,943,000. Hedge funds and other institutional investors own 32.46% of the company’s stock.

Galapagos Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.